Compare FEAM & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEAM | MREO |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.9M | 50.3M |
| IPO Year | 2022 | 2017 |
| Metric | FEAM | MREO |
|---|---|---|
| Price | $3.23 | $0.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $3.75 | $1.96 |
| AVG Volume (30 Days) | 648.7K | ★ 1.6M |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.80 | 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,000.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $0.20 |
| 52 Week High | $7.50 | $2.37 |
| Indicator | FEAM | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 79.33 | 69.92 |
| Support Level | $1.31 | $0.28 |
| Resistance Level | $4.11 | $0.42 |
| Average True Range (ATR) | 0.30 | 0.03 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 95.96 | 81.65 |
5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).